logo-loader

Canafarma announces tie-up with Dutch pharma group to develop new approaches to deliver hemp-based cannabinoids

Last updated: 14:33 16 Sep 2020 EDT, First published: 10:55 16 Sep 2020 EDT

Canafarma -
Canafarma CEO David Lonsdale said he was "delighted" to be working with APeT and the initial focus will be on anti-viral, immune boosting and anti-aging formulations to boost the firm's consumer product brands

Canafarma Hemp Products Corp (CSE:CNFA) unveiled a tie-up with Dutch pharma group APeT BV to develop new approaches to deliver its hemp-based products to people.

ApeT BV is the firm behind the patented FLOTEX‐C system, where active ingredients are delivered in a time released manner via a capsule that 'floats' within the stomach.

READ: Canafarma Hemp Products says record producer who has worked with Snoop Dogg and Jason Deroulo will spearhead the firm's media efforts

The pair will develop novel hemp-based cannabinoid, drug, and nutritional supplement delivery methods through the technology.

"We are delighted to be working with APeT on something so important to the industry, and our initial focus will be on anti-viral, immune boosting and anti-aging formulations to further develop the company's consumer product brands," said David Lonsdale, CEO of Canafarma in a statement.

Many patients suffer side effects from medication or a lack of efficacy, added to which there are compliance challenges such as too many pills spread over different hours of intake per day that can lead to people skipping, or forgetting to take the right amount of medication at the right time, said the company.

"Canafarma and APeT's use of the FLOTEX‐C technology will be designed with the objective of resolving many of these problems," said Canafarma.

Canafarma Hemp Products is a full-service company operating in the hemp industry offering a full range of hemp-related products and services to the consumer wellness market.

Shares were boosted over 6% in Toronto to C$0.51 each on the day.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

14 hours, 7 minutes ago